The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 5 of 6

Previous | 1 | 2 | 3 | 4 | 5 | 6 | Next

Time/Date Code Headline Source Impact
08:57 25-Feb-2016 AZN ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED RNS +0.55% Up
07:05 19-Feb-2016 AZN BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS RNS -0.76% Down
07:00 19-Feb-2016 AZN ZURAMPIC APPROVED IN EU FOR GOUT PATIENTS RNS -0.76% Down
07:00 17-Feb-2016 AZN Durvalumab granted BTD by FDA for cancer patients RNS +1.83% Up
08:01 16-Feb-2016 AZN NEW EXTERNAL BOARD APPOINTMENT RNS +3.47% Up
07:00 04-Feb-2016 AZN AstraZeneca Full-Year and Q4 2015 Results RNS -9.74% Down
09:00 03-Feb-2016 AZN Notice of Results RNS -8.18% Down
07:00 03-Feb-2016 AZN TAGRISSO approved in EU for cancer patients RNS -8.18% Down
09:05 02-Feb-2016 AZN AZ Completes transaction with Acerta Pharma RNS -5.21% Down
14:32 01-Feb-2016 AZN Total Voting Rights RNS -2.24% Down
07:00 28-Jan-2016 AZN Lynparza Granted BTD in US for Prostate Cancer RNS +1.31% Up
14:00 04-Jan-2016 AZN Director/PDMR Shareholding RNS -3.50% Down
14:00 04-Jan-2016 AZN Director/PDMR Shareholding RNS -3.50% Down
13:30 04-Jan-2016 AZN Total Voting Rights RNS -3.50% Down
16:30 23-Dec-2015 AZN Result of External Audit Tender RNS +3.72% Up
07:00 23-Dec-2015 AZN LESINURAD APPROVED BY US FDA FOR GOUT RNS +3.72% Up
12:41 18-Dec-2015 AZN TAGRISSOT (OSIMERTINIB) POSITIVE CHMP OPINION RNS +1.51% Up
12:41 18-Dec-2015 AZN BRILIQUE (TICAGRELOR) POSITIVE EU CHMP OPINION RNS +1.51% Up
12:40 18-Dec-2015 AZN CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT RNS +1.51% Up
07:00 18-Dec-2015 AZN ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY RNS +1.51% Up

 Page 5 of 6

Previous | 1 | 2 | 3 | 4 | 5 | 6 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 54,011.39
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
11-Dec-16
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)